1. M19 Differences in patient and physician viewpoints of the management of idiopathic pulmonary fibrosis (ipf). (15th November 2017) Authors: Maher, TM; Swigris, JJ; Kreuter, M; Wijsenbeek, M; Axmann, J; Ireland, L; Nathan, SD Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P174 Effect of continued treatment with pirfenidone following a ≥10% relative decline in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF). (15th November 2016) Authors: Wells, AU; Albera, C; Costabel, U; Glaspole, I; Glassberg, MK; Lancaster, L; Lederer, DJ; Pereira, CA; Swigris, JJ; Day, B-M; Chou, W; Nathan, SD Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S97 Annual rate of fvc decline in various patient sub-groups with idiopathic pulmonary fibrosis treated with pirfenidone: pooled analysis from 3 pivotal studies. (15th November 2016) Authors: Noble, PW; Albera, C; Chou, W; Costabel, U; Day, B; Glaspole, I; Glassberg, MK; Lancaster, L; Lederer, DJ; Nathan, SD; Pereira, CA; Stauffer, J; Swigris, JJ Journal: Thorax Issue: Volume 71(2016)Supplement 3 Page Start: A57 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P13 Safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Integrated analysis of cumulative data from 5 clinical trials. (12th November 2015) Authors: Noble, PW; Albera, C; Bradford, WZ; Costabel, U; Glaspole, I; Glassberg, MK; Lederer, DJ; Lin, Z; Nathan, SD; Pereira, CA; Swigris, JJ; Valeyre, D; Lancaster, L Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. M32 Effect of pirfenidone on all-cause mortality (acm) and forced vital capacity (fvc) in idiopathic pulmonary fibrosis (ipf) patients with low fvc and/or low dlco: analysis of pooled data from ascend and capacity. (15th November 2017) Authors: Nathan, SD; Costabel, U; Albera, C; Kirchgaessler, KU; Chou, W; Noble, PW Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S109 Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF). (12th November 2015) Authors: Noble, PW; Albera, C; Bradford, WZ; Costabel, U; Glaspole, I; Glassberg, MK; Lancaster, L; Lederer, DJ; Lin, Z; Pereira, CA; Swigris, JJ; Valeyre, D; Nathan, SD Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P14 Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) with more preserved lung function. (12th November 2015) Authors: Noble, PW; Bradford, WZ; Costabel, U; Glaspole, I; Glassberg, MK; Gorina, E; Kardatzke, D; Lancaster, L; Lederer, DJ; Nathan, SD; Pereira, C; Spirig, D; Swigris, JJ; Valeyre, D; Albera, C Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗